Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;6(2):E34-6.
doi: 10.3978/j.issn.2078-6891.2014.113.

Transition of a pancreatic neuroendocrine tumor from ghrelinoma to insulinoma: a case report

Aman Chauhan  1 , Robert A Ramirez  1 , Melissa A Stevens  1 , Leigh Anne Burns  1 , Eugene A Woltering  1
Affiliations

Transition of a pancreatic neuroendocrine tumor from ghrelinoma to insulinoma: a case report

Aman Chauhan et al. J Gastrointest Oncol. 2015 Apr.

Abstract

Pancreatic neuroendocrine tumors (PNETs) are rare with an incidence of 1 in 100,000 populations. PNETs can present either as a functional or non-functional tumor. In functional tumors the symptoms are a result of hormones such as insulin, gastrin, glucagon and vasoactive intestinal peptide (VIP) or others. Ghrelin is a 28 amino acid peptide discovered in 1999 and is thought to be involved in various physiologic and pathologic processes. Due to relatively recent discovery of this hormone, its functions in normal homeostasis and its association with various pathologic processes are still being uncovered. PNETs are a rare entity and the natural history of disease is not well known. We have presented a first ever case of metastatic PNET which presented as a ghrelinoma and later transformed into a symptomatic insulinoma. This case gives us a glimpse into an unusual variant of metastatic PNET. It also tells us that change in functional tumor biology can sometime be more morbid than the metastatic disease itself.

Keywords: Pancreatic neuroendocrine tumor (PNET); ghrelinoma; insulinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MRI of abdomen with contrast showing metastatic disease to liver. MRI, magnetic resonance imaging.
Figure 2
Figure 2
MIBG scan showing metastatic disease in liver. MIBG, iodine-131-meta-iodobenzylguanidine.
Figure 3
Figure 3
Plot of insulin levels on right and ghrelin levels on left.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75. - PMC - PubMed
    1. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13-27. - PubMed
    1. Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 2007;142:347-54. - PMC - PubMed
    1. Vu JP, Wang HS, Germano PM, et al. Ghrelin in neuroendocrine tumors. Peptides 2011;32:2340-7. - PMC - PubMed
    1. Cheung CK, Wu JC. Role of ghrelin in the pathophysiology of gastrointestinal disease. Gut Liver 2013;7:505-12. - PMC - PubMed